Indication
Growth failure due to achondroplasia
Growth failure due to achondroplasia is a skeletal manifestation characterized by severely impaired linear bone growth and disproportionate short stature in pediatric patients with open epiphyses. Read more about Growth failure due to achondroplasia
2 drugs 2 manufacturers
Drugs that treat it
Common Growth failure due to achondroplasia therapies.
YUVIWEL (navepegritide)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonGrowth failure due to achondroplasia is a skeletal manifestation characterized by severely impaired linear bone growth and disproportionate short stature in pediatric patients with open epiphyses.
It is driven by autosomal dominant, gain-of-function mutations in the fibroblast growth factor receptor 3 (*FGFR3*) gene, which lead to constitutive overactivation of downstream intracellular signaling pathways that suppress chondrocyte proliferation and differentiation within the cartilaginous growth plates.
This pathophysiologic cascade disrupts normal endochondral ossification, predominantly impairing long bone elongation.
Clinically, affected individuals present with rhizomelic limb shortening, macrocephaly with frontal bossing, midface hypoplasia, and an increased susceptibility to cervicomedullary compression and spinal stenosis.
- nih.gov
Growth failure due to achondroplasia is a skeletal manifestation characterized by severely impaired linear bone growth and disproportionate short stature in pediatric patients with open epiphyses Clinically, affected individuals present with rhizomelic limb shortening, macrocephaly with frontal bossing, midface hypoplasia, and an increased susceptibility to cervicomedullary compression and spinal stenosis
- fda.gov
Growth failure due to achondroplasia is a skeletal manifestation characterized by severely impaired linear bone growth and disproportionate short stature in pediatric patients with open epiphyses
- fda.gov
It is driven by autosomal dominant, gain-of-function mutations in the fibroblast growth factor receptor 3 (*FGFR3*) gene, which lead to constitutive overactivation of downstream intracellular signaling pathways that suppress chondrocyte proliferation and differentiation within the cartilaginous growth plates
- nih.gov
It is driven by autosomal dominant, gain-of-function mutations in the fibroblast growth factor receptor 3 (*FGFR3*) gene, which lead to constitutive overactivation of downstream intracellular signaling pathways that suppress chondrocyte proliferation and differentiation within the cartilaginous growth plates This pathophysiologic cascade disrupts normal endochondral ossification, predominantly impairing long bone elongation
- nih.gov
This pathophysiologic cascade disrupts normal endochondral ossification, predominantly impairing long bone elongation
- orthobullets.com
Clinically, affected individuals present with rhizomelic limb shortening, macrocephaly with frontal bossing, midface hypoplasia, and an increased susceptibility to cervicomedullary compression and spinal stenosis
Personalize your experience
Follow Growth failure due to achondroplasia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.